Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of AK156 (Reclast) in Primary Osteoporosis
NCT01522521Phase 3Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Feb 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteoporosis comparing AK156 with Placebo (2 arms). Primary endpoint: Incidence of new vertebral fractures at 2 years. Started Feb 2012; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT01522521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522521.